Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia Intensiva


Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Nidia Zapata, MD, associate professor, Instituto Nacional de Cancerologia, discusses the implications of the phase 3 VIALE-A trial (NCT02993523) of venetoclax (Venclexta) plus azacitidine (Vidaza) vs azacitidine alone in treatment-naïve patients with acute myeloid leukemia (AML) who are ineligible for standard induction therapy.

Zapata: The results of the VIALE-A study…helped us understand the benefit of intensive treatment in patients with AML. This has led to a radical change in the treatment of these patients, as we now know that this combination allows patients who were not candidates for intensive chemotherapy to have a better quality of life and overall survival

In the long-term, this can lead to a dynamic improvement in the physical performance of patients who were initially not eligible for intensive treatment. [Venetoclax plus azacitidine] improved [patients’] quality of life [and] physical performance. [It] even makes them even candidates for reduced-intensity bone marrow transplantation, resulting in improved survival, quality of life, and overall benefit for these patients.

Editor's Note: Dr Zapata's transcript has been translated from Spanish to English.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD